Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C31H44O8 |
| Molecular Weight | 544.6763 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 12 / 12 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@@]2(C)C(CC[C@]3([H])[C@]2([H])CC[C@]4(C)[C@H](CC[C@]34O)C5=COC(=O)C=C5)=C1)O[C@@H]6O[C@@H](C)[C@H](OC)[C@@H](O)[C@H]6O
InChI
InChIKey=RKWPZPDLTYBKCL-RVZGXXANSA-N
InChI=1S/C31H44O8/c1-17-27(36-4)25(33)26(34)28(38-17)39-20-9-12-29(2)19(15-20)6-7-23-22(29)10-13-30(3)21(11-14-31(23,30)35)18-5-8-24(32)37-16-18/h5,8,15-17,20-23,25-28,33-35H,6-7,9-14H2,1-4H3/t17-,20-,21+,22-,23+,25-,26+,27-,28-,29-,30+,31-/m0/s1
Meproscillarin is a semisynthetic glycoside for the therapy of cardiac insufficiency. Meproscillarin is a drug with a high bioavailability (about 70%). Meproscillarin is at the only non-renal eliminated, lipophilic and short half-life digitalis and is therefore an ideal, cardiac inotropic agent for use in renal insufficiency. Meproscillarin can be used therapeutically in patients with liver cirrhosis, because a toxic accumulation is not to be expected. The rate of side effects of meproscillarin corresponded to that of other cardiac glycosides.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C78322
Created by
admin on Fri Dec 15 16:47:24 GMT 2023 , Edited by admin on Fri Dec 15 16:47:24 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
251-493-6
Created by
admin on Fri Dec 15 16:47:24 GMT 2023 , Edited by admin on Fri Dec 15 16:47:24 GMT 2023
|
PRIMARY | |||
|
100000081500
Created by
admin on Fri Dec 15 16:47:24 GMT 2023 , Edited by admin on Fri Dec 15 16:47:24 GMT 2023
|
PRIMARY | |||
|
15942714
Created by
admin on Fri Dec 15 16:47:24 GMT 2023 , Edited by admin on Fri Dec 15 16:47:24 GMT 2023
|
PRIMARY | |||
|
m9255
Created by
admin on Fri Dec 15 16:47:24 GMT 2023 , Edited by admin on Fri Dec 15 16:47:24 GMT 2023
|
PRIMARY | Merck Index | ||
|
1705
Created by
admin on Fri Dec 15 16:47:24 GMT 2023 , Edited by admin on Fri Dec 15 16:47:24 GMT 2023
|
PRIMARY | |||
|
C87688
Created by
admin on Fri Dec 15 16:47:24 GMT 2023 , Edited by admin on Fri Dec 15 16:47:24 GMT 2023
|
PRIMARY | |||
|
4012
Created by
admin on Fri Dec 15 16:47:24 GMT 2023 , Edited by admin on Fri Dec 15 16:47:24 GMT 2023
|
PRIMARY | |||
|
DTXSID101031613
Created by
admin on Fri Dec 15 16:47:24 GMT 2023 , Edited by admin on Fri Dec 15 16:47:24 GMT 2023
|
PRIMARY | |||
|
WYR1723LO7
Created by
admin on Fri Dec 15 16:47:24 GMT 2023 , Edited by admin on Fri Dec 15 16:47:24 GMT 2023
|
PRIMARY | |||
|
C009079
Created by
admin on Fri Dec 15 16:47:24 GMT 2023 , Edited by admin on Fri Dec 15 16:47:24 GMT 2023
|
PRIMARY | |||
|
SUB08758MIG
Created by
admin on Fri Dec 15 16:47:24 GMT 2023 , Edited by admin on Fri Dec 15 16:47:24 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106427
Created by
admin on Fri Dec 15 16:47:24 GMT 2023 , Edited by admin on Fri Dec 15 16:47:24 GMT 2023
|
PRIMARY | |||
|
33396-37-1
Created by
admin on Fri Dec 15 16:47:24 GMT 2023 , Edited by admin on Fri Dec 15 16:47:24 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
